Cited by 378Substance Abuse Treatment and OutcomesMental Health Treatment and AccessPsychiatric care and mental health services

Integrated treatment of substance use and psychiatric disorders

Open access
Kelly, Thomas M., Daley, Dennis C.·2013·Social Work in Public Health

Abstract

Epidemiological studies find that psychiatric disorders, including mental disorders and substance use disorders, are common among adults and highly comorbid. Integrated treatment refers to the focus of treatment on two or more conditions and to the use of multiple treatments such as the combination of psychotherapy and pharmacotherapy. Integrated treatment for comorbidity has been found to be consistently superior compared to treatment of individual disorders with separate treatment plans. This article focuses on a review of the risks for developing comorbid disorders and the combinations of treatments that appear to be most effective for clients with particular comorbid disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19371918.2013.774673

Cites

147 of 147 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Combined interventions for psychiatric disorders and SUDs may be more effective, less burdensome, and less costly than separate treatment plans.

    “Combined interventions for psychiatric disorders and SUDs may therefore be more effective, less burdensome, and less costly than separate treatment plans, so integrated treatments that address opioid use and common co-morbidities may enhance long-term retention 6.”

    From Effects of a trauma-informed mindful recovery program on comorbid pain, anxiety, and substance use during primary care buprenorphine treatment: A proof-of-concept study (2023) · cites this paper as [6]

    The Introduction says integrated treatment is superior to separate, single-focused treatment for co-occurring psychiatric and substance use disorders. The passages do not establish that it is less burdensome or less costly; searches for cost and burden found no supporting passage. No page numbers were supplied in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Previous reviews have found integrated treatments more effective than parallel or single disorder options.

    “We anticipated that integrated versus non-integrated treatments would be a significant moderator of anxiety and substance use as previous reviews have found integrated treatments more effective then parallel or single disorder options.(Kelly & Daley, 2013; Mangrum et al., 2006; Mueser, 2003; Torchalla et al., 2012; van Wamel et al., 2015; Yule & Kelly, 2019)”
  • Modafinil activates glutamatergic circuits while inhibiting GABA.

    “Modafinil also activates glutamatergic circuits while inhibiting GABA.130,131”

    From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [131]

    The section on neurological and psychological interactions discusses dopamine, serotonin, and endocannabinoids, but does not address modafinil’s effects on glutamatergic circuits or GABA. Searches for modafinil and for glutamate/GABA returned no passage supporting the claim; our copy does not settle it. (LLM, conf=0.72)

    Experimental — accuracy not yet measured
  • The exact mechanism of modafinil is unclear, but in vitro studies show that it modulates multiple neurotransmitter systems, including dopamine, serotonin, and norepinephrine reuptake, as well as histamine and hypocretin signaling.

    “The exact mechanism of action of modafinil is unclear, though in vitro studies have shown that it modulates multiple neurotransmitter systems, including dopamine, serotonin, and norepinephrine reuptake, as well as histamine and hypocretin signaling.”

    From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [131]

    The section “Neurological and Psychological Interaction of SUD and Non-SUD Psychiatric Disorders” discusses dopamine in drugs of abuse and serotonin in alcohol and ecstasy, not modafinil. Searches for modafinil, its proposed in vitro mechanism, histamine, and hypocretin found no passage addressing the claim in our copy; page numbers were unavailable. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Daley DC Thase ME 2004 Dual disorders recovery counseling: Integrated treatment for substance use & mental health disorders 3 Independence, MO Independence Press
  2. Weiss RD Connery HS 2011 Integrated group therapy for bipolar disorders and substance abuse New York, NY Guilford Press

Cited by

Sorted by citations

Authors
Kelly, T. M., & Daley, D. C.
Affiliations
University of Pittsburgh Medical Center (US)
Venue
Social Work in Public Health
Published
2013-05
Volume
28
Issue
3-4
Pages
388-406
ISSN
  • 1937-190X (ISSN-L)
  • 1937-1918
OpenAlex
W2039958472
Cited by
378
References
147
Citations by year
2026: 39 · 2025: 47 · 2024: 50 · 2023: 40 · 2022: 52 · 2021: 44 · 2020: 32 · 2019: 38 · 2018: 15 · 2017: 11 · 2016: 5 · 2015: 4 · 2014: 1
FWCI
2.43
Type
journal article
Language
en
Open access
Locations
  • Social Work in Public Health (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5u10da020036-10)
  • National Institute on Drug Abuse (U10-DA020036)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
  • Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
Keywords
integrated treatment, substance use disorders, mental illness, comorbidities, psychotherapy, pharmacotherapy, treatment effectiveness
MeSH terms
Adult, Mental Disorders, Combined Modality Therapy, Humans, Psychotherapy, Delivery of Health Care, Integrated, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review